Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
beta-D-Galactosamine is an amino sugar and a deoxygalactose derivative, specifically a hexose monosaccharide in which the hydroxy group at position 2 of beta-D-galactose is replaced by an amino group. It occurs as a metabolite in Escherichia coli and is functionally related to beta-D-galactose. In experimental settings, galactosamine (including the D-form) is used to induce liver injury in animal models by interfering with uridine nucleotide pools essential for RNA and protein synthesis. This hepatotoxic effect results from its metabolism via the Leloir pathway, leading to depletion of uridine triphosphate (UTP) and other uridine derivatives necessary for cellular function[1][6]. There are no approved medical indications or clinical uses for this compound as a pharmaceutical agent[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on beta-D-galactosamine.